E-resources
Peer reviewed
Open access
-
Datoo, Mehreen S; Dicko, Alassane; Tinto, Halidou; Ouédraogo, Jean-Bosco; Hamaluba, Mainga; Olotu, Ally; Ramos Lopez, Fernando; Natama, Hamtandi Magloire; Weston, Sophie; Chemba, Mwajuma; Compaore, Yves Daniel; Issiaka, Djibrilla; Salou, Diallo; Omenda, Sharon; Bejon, Philip; Rao, Harish; Chandramohan, Daniel; Roberts, Rachel; Bharati, Sandesh; Gairola, Sunil; Greenwood, Brian M; Ewer, Katie J; Bradley, John; Shaligram, Umesh; Mahamar, Almahamoudou; Sanogo, Koualy; Sidibe, Youssoufa; Diarra, Kalifa; Samassekou, Mamoudou; Tapily, Amadou; Diallo, Makonon; Dicko, Oumar Mohamed; Kaya, Mahamadou; Maguiraga, Seydina Oumar; Yalcouye, Hama; Niambele, Sidi Mohamed; Thera, Ismaila; Sagara, Issaka; Sylla, Mala; Dolo, Amagana; Simando, Sylvester; Msami, Hania; Juma, Omary; Gutapaka, Nicolaus; Mswata, Sarah; Sasamalo, Ibrahim; Johaness, Kasmir; Sultan, Mwantumu; Alexander, Annastazia; Kimaro, Isaac; Lwanga, Kauye; Mtungwe, Mwajuma; Khamis, Kassim; Rugarabam, Lighton; Kalinga, Wilmina; Mohammed, Mohammed; Kamange, Janeth; Msangi, Jubilate; Mwaijande, Batuli; Mtaka, Ivanny; Mhapa, Matilda; Mlaganile, Tarsis; Yerbanga, Rakiswende Serge; Samtouma, Wendkouni; Sienou, Abdoul Aziz; Kabre, Zachari; Ouedraogo, Wendinpui Jedida Muriel; Yarbanga, G Armel Bienvenu; Zongo, Issaka; Savadogo, Hamade; Sanon, Joseph; Compaore, Judicael; Yoni, Ferdinand Lionel; Sanre, Tewende Martine; Ouattara, Seydou Bienvenu; Woods, Danielle; Snow, Robert W.; Amek, Nyaguara; Ngetsa, Caroline J.; Musyoki, Jennifer; Munene, Marianne; Mumba, Noni; Mwawaka, Jimmy Shangala; Mwaganyuma, Mwatasa Hussein; Ndichu, Martha Njeri; Weya, Joseph Ochieng; Njogu, Kelvin; Grant, Jane; Webster, Jayne; Lakhkar, Anand; Ido, N. Félix André; Traore, Ousmane; Bonko, Massa dit Achille; Rouamba, Toussaint; Ouedraogo, D. Florence; Soma, Rachidatou; Millogo, Aida; Ouedraogo, Edouard; Sorgho, Faizatou; Valea, Innocent
Lancet, 02/2024, Volume: 403, Issue: 10426Journal Article
Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites. We did a double-blind, randomised, phase 3 trial of the R21/Matrix-M malaria vaccine across five sites in four African countries with differing malaria transmission intensities and seasonality. Children (aged 5–36 months) were enrolled and randomly assigned (2:1) to receive 5 μg R21 plus 50 μg Matrix-M or a control vaccine (licensed rabies vaccine Abhayrab). Participants, their families, investigators, laboratory teams, and the local study team were masked to treatment. Vaccines were administered as three doses, 4 weeks apart, with a booster administered 12 months after the third dose. Half of the children were recruited at two sites with seasonal malaria transmission and the remainder at standard sites with perennial malaria transmission using age-based immunisation. The primary objective was protective efficacy of R21/Matrix-M from 14 days after third vaccination to 12 months after completion of the primary series at seasonal and standard sites separately as co-primary endpoints. Vaccine efficacy against multiple malaria episodes and severe malaria, as well as safety and immunogenicity, were also assessed. This trial is registered on ClinicalTrials.gov, NCT04704830, and is ongoing. From April 26, 2021, to Jan 12, 2022, 5477 children consented to be screened, of whom 1705 were randomly assigned to control vaccine and 3434 to R21/Matrix-M; 4878 participants received the first dose of vaccine. 3103 participants in the R21/Matrix-M group and 1541 participants in the control group were included in the modified per-protocol analysis (2412 51·9% male and 2232 48·1% female). R21/Matrix-M vaccine was well tolerated, with injection site pain (301 18·6% of 1615 participants) and fever (754 46·7% of 1615 participants) as the most frequent adverse events. Number of adverse events of special interest and serious adverse events did not significantly differ between the vaccine groups. There were no treatment-related deaths. 12-month vaccine efficacy was 75% (95% CI 71–79; p<0·0001) at the seasonal sites and 68% (61–74; p<0·0001) at the standard sites for time to first clinical malaria episode. Similarly, vaccine efficacy against multiple clinical malaria episodes was 75% (71–78; p<0·0001) at the seasonal sites and 67% (59–73; p<0·0001) at standard sites. A modest reduction in vaccine efficacy was observed over the first 12 months of follow-up, of similar size at seasonal and standard sites. A rate reduction of 868 (95% CI 762–974) cases per 1000 children-years at seasonal sites and 296 (231–362) at standard sites occurred over 12 months. Vaccine-induced antibodies against the conserved central Asn-Ala-Asn-Pro (NANP) repeat sequence of circumsporozoite protein correlated with vaccine efficacy. Higher NANP-specific antibody titres were observed in the 5–17 month age group compared with 18–36 month age group, and the younger age group had the highest 12-month vaccine efficacy on time to first clinical malaria episode at seasonal (79% 95% CI 73–84; p<0·001) and standard (75% 65–83; p<0·001) sites. R21/Matrix-M was well tolerated and offered high efficacy against clinical malaria in African children. This low-cost, high-efficacy vaccine is already licensed by several African countries, and recently received a WHO policy recommendation and prequalification, offering large-scale supply to help reduce the great burden of malaria in sub-Saharan Africa. The Serum Institute of India, the Wellcome Trust, the UK National Institute for Health Research Oxford Biomedical Research Centre, and Open Philanthropy.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.